A systematic review found that bilateral salpingectomy is associated with roughly an 80% reduction in risk for the serous ...

The province is expanding access to a life-saving made-in-B.C. procedure that dramatically reduces the risk of occurrence of ovarian cancer.

Women with certain genetic mutations are at extremely high risk of ovarian cancer. Now, some researchers are trying a new ...

Social media is shaping IVF decisions, but not always correctly. Fertility specialist Dr Madhulika Singh explains the most ...

University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for providing insights into molecular changes linked to early ovarian cancer ...

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in ...

Sofetabart mipitecan received FDA breakthrough therapy designation for platinum-resistant ovarian cancer after prior ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

Eli Lilly has won U.S. Food and Drug Administration breakthrough -therapy designation for its sofetabart mipitecan drug candidate for certain patients with ovarian cancer.

Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.

The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...